Kidney Cancer

Kidney cancer is one of the 10 most common cancers to affect men and women. It is more common in older people. The average age of those diagnosed with kidney cancer is 64 years old. The American Cancer Society (ACS) estimates that in 2023, approximately 81,800 people will be diagnosed with kidney cancer in the U.S. Approximately 14,890 people are predicted to die from cancer of the kidney and renal pelvis in 2023.1

Please visit the following sections to learn more about kidney cancer:

  • 1. American Cancer Society.Cancer Facts & Figures 2023. Atlanta: American Cancer Society. (2023). Retrieved from https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2023-cancer-facts-figures.html
  • 2.a. b. Ogobuiro, I., & Tuma, F. (2019). Physiology, Renal.. FL: Treasure Island: StatPearls Publishing. [PUBMED]
  • 3.a. b. Arthur JM, Thongboonkerd V, Scherzer JA, Cai J, Pierce WM, Klein JB. Differential expression of proteins in renal cortex and medulla: a proteomic approach. Kidney Int. 2002 Oct;62(4):1314-21. [PUBMED]
  • 4.a. b. c. d. Scelo G, Riazalhosseini Y, Greger L, Letourneau L, Gonzàlez-Porta M, Wozniak MB, Bourgey M, Harnden P, Egevad L, Jackson SM, Karimzadeh M, Arseneault M, Lepage P, How-Kit A, Daunay A, Renault V, Blanché H, Tubacher E, Sehmoun J, Viksna J, Celms E, Opmanis M, Zarins A, Vasudev NS, Seywright M, Abedi-Ardekani B, Carreira C, Selby PJ, Cartledge JJ, Byrnes G, Zavadil J, Su J, Holcatova I, Brisuda A, Zaridze D, Moukeria A, Foretova L, Navratilova M, Mates D, Jinga V, Artemov A, Nedoluzhko A, Mazur A, Rastorguev S, Boulygina E, Heath S, Gut M, Bihoreau MT, Lechner D, Foglio M, Gut IG, Skryabin K, Prokhortchouk E, Cambon-Thomsen A, Rung J, Bourque G, Brennan P, Tost J, Banks RE, Brazma A, Lathrop GM. Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nat Commun. 2014 Oct 29;5:5135. doi: 10.1038/ncomms6135. [PUBMED]
  • 5.a. b. c. d. e. f. g. h. i. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010 May;7(5):245-57. doi: 10.1038/nrurol.2010.46. [PUBMED]
  • 6.a. b. c. d. e. f. ACS 2014 Kidney Cancer Detailed Guide [http://www.cancerquest.org/sites/default/files/assets/pdf/Kidney/kidney-cancer-detailed-guide-acs.pdf]
  • 7. What are the key statistics about Wilms tumor? American Cancer Society. [http://www.cancer.org/cancer/wilmstumor/detailedguide/wilms-tumor-key-statistics]
  • 8.a. b. Maschietto, M., Charlton, J., Perotti, D., Radice, P., Geller, J., Pritchard-Jones, K., & Weeks, M. (2014). The IGF signalling pathway in Wilms tumours--a report from the ENCCA Renal Tumours Biology-driven drug development workshop. Oncotarget, 5(18), 8014–26. (Original work published September 2014) [PUBMED]
  • 9. Genetics of Kidney Cancer (Renal Cell Cancer). National Cancer Institute at the National Institutes of Health. U.S. Department of Health and Human Services. [http://www.cancer.gov/cancertopics/pdq/genetics/kidney/HealthProfessional/page1]
  • 10. Major Heritable Renal Cell Cancer Syndromes. National Cancer Institute at the National Institutes of Health. U.S. Department of Health and Human Services. [http://www.cancer.gov/cancertopics/pdq/genetics/kidney/HealthProfessional/page2]
  • 11.a. b. Hanks S, Perdeaux ER, Seal S, Ruark E, Mahamdallie SS, Murray A, Ramsay E, Del Vecchio Duarte S, Zachariou A, de Souza B, Warren-Perry M, Elliott A, Davidson A, Price H, Stiller C, Pritchard-Jones K, Rahman N. Germline mutations in the PAF1 complex gene CTR9 predispose to Wilms tumour. Nat Commun. 2014 Aug 7;5:4398. doi: 10.1038/ncomms5398. [PUBMED]
  • 12.a. b. c. Wilms Tumor and Other Childhood Kidney Tumors Treatment. National Cancer Institute at the National Institutes of Health. U.S. Department of Health and Human Services. [http://www.cancer.gov/cancertopics/pdq/treatment/wilms/HealthProfessional/page2]
  • 13. Gronskov K, Olsen JH, Sand A, Pedersen W, Carlsen N, Bak Jylling AM, Lyngbye T, Brondum-Nielsen K, Rosenberg T. Population-based risk estimates of Wilms tumor in sporadic aniridia. A comprehensive mutation screening procedure of PAX6 identifies 80% of mutations in aniridia. Hum Genet. 2001 Jul;109(1):11-8. [PUBMED]
  • 14. Scott RH, Walker L, Olsen OE, Levitt G, Kenney I, Maher E, Owens CM, Pritchard-Jones K, Craft A, Rahman N. Surveillance for Wilms tumour in at-risk children: pragmatic recommendations for best practice. Arch Dis Child. 2006 Dec;91(12):995-9. Epub 2006 Jul 20. [PUBMED]
  • 15. Trichloroethylene. Household Products Database. U.S. Department of Health and Human Services. [http://hpd.nlm.nih.gov/cgi-bin/household/search?tbl=TblChemicals&queryx=79-01-6]
  • 16. Kidney Cancer Prevention. Mayo Clinic. [http://www.mayoclinic.org/diseases-conditions/kidney-cancer/basics/prevention/con-20024753]
  • 17. Boffetta P, Fontana L, Stewart P, Zaridze D, Szeszenia-Dabrowska N, Janout V, Bencko V, Foretova L, Jinga V, Matveev V, Kollarova H, Ferro G, Chow WH, Rothman N, van Bemmel D, Karami S, Brennan P, Moore LE. Occupational exposure to arsenic, cadmium, chromium, lead and nickel, and renal cell carcinoma: a case-control study from Central and Eastern Europe. Occup Environ Med. 2011 Oct;68(10):723-8. doi: 10.1136/oem.2010.056341. Epub 2011 Jan 8. [PUBMED]
  • 18. ACS 2014 Kidney Cancer Overview Guide [/sites/default/files/assets/pdf/Kidney/kidney-cancer-overview-guide-acs.pdf]
  • 19. VHL. Genetics Home Reference. National Institutes of Health. U.S. Department of Health and Human Services. Reviewed August 2012, Published August 2015 [http://ghr.nlm.nih.gov/gene/VHL]
  • 20.a. b. Zhuang J, Tu X, Cao K, Guo S, Mao X, Pan J, Huang B, Chen X, Gao Y, Qiu S. The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma. J Exp Clin Cancer Res. 2014 Mar 7;33:25. doi: 10.1186/1756-9966-33-25. [PUBMED]
  • 21. Cowey CL, Rathmell WK. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep. 2009 Mar;11(2):94-101. [PUBMED]
  • 22. Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruine AP. VHL and HIF signalling in renal cell carcinogenesis. J Pathol. 2010 Jun;221(2):125-38. doi: 10.1002/path.2689. [PUBMED]
  • 23. Shahzad H, Kehar SI, Ali S, Tariq N. Expression of Von Hippel - Lindau (VHL) gene mutation in diagnosed cases of renal cell carcinoma. Pak J Med Sci. 2014 Jul;30(4):880-5. [PUBMED]
  • 24. Choueiri TK, Fay AP, Gagnon R, Lin Y, Bahamon B, Brown V, Rosenberg JE, Hutson TE, Baker-Neblett KL, Carpenter C, Liu Y, Pandite L, Signoretti S. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res. 2013 Sep 15;19(18):5218-26. doi: 10.1158/1078-0432.CCR-13-0491. Epub 2013 Jul 23. [PUBMED]
  • 25. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, Bignell G, Butler A, Cho J, Dalgliesh GL, Galappaththige D, Greenman C, Hardy C, Jia M, Latimer C, Lau KW, Marshall J, McLaren S, Menzies A, Mudie L, Stebbings L, Largaespada DA, Wessels LF, Richard S, Kahnoski RJ, Anema J, Tuveson DA, Perez-Mancera PA, Mustonen V, Fischer A, Adams DJ, Rust A, Chan-on W, Subimerb C, Dykema K, Furge K, Campbell PJ, Teh BT, Stratton MR, Futreal PA. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011 Jan 27;469(7331):539-42. doi: 10.1038/nature09639. Epub 2011 Jan 19. [PUBMED]
  • 26. Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, Leng N, Pavía-Jiménez A, Wang S, Yamasaki T, Zhrebker L, Sivanand S, Spence P, Kinch L, Hambuch T, Jain S, Lotan Y, Margulis V, Sagalowsky AI, Summerour PB, Kabbani W, Wong SW, Grishin N, Laurent M, Xie XJ, Haudenschild CD, Ross MT, Bentley DR, Kapur P, Brugarolas J. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet. 2012 Jun 10;44(7):751-9. doi: 10.1038/ng.2323. [PUBMED]
  • 27. Zigeuner R, Ratschek M, Rehak P, Schips L, Langner C. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology. 2004 Apr;63(4):651-5. [PUBMED]
  • 28. Villaamil VM, Gallego GA, Caínzos IS, Ruvira LV, Valladares-Ayerbes M, Aparicio LM. Relevant Networks involving the p53 Signalling Pathway in Renal Cell Carcinoma. Int J Biomed Sci. 2011 Dec;7(4):273-82. [PUBMED]
  • 29. Sitaram RT, Degerman S, Ljungberg B, Andersson E, Oji Y, Sugiyama H, Roos G, Li A. Wilms' tumour 1 can suppress hTERT gene expression and telomerase activity in clear cell renal cell carcinoma via multiple pathways. Br J Cancer. 2010 Oct 12;103(8):1255-62. doi: 10.1038/sj.bjc.6605878. Epub 2010 Sep 14. [PUBMED]
  • 30. Niu Z, Ito M, Awakura Y, Takahashi T, Nakamura E, Ito N, Ogawa O. The expression of NOV and WT1 in renal cell carcinoma: a quantitative reverse transcriptase-polymerase chain reaction analysis. J Urol. 2005 Oct;174(4 Pt 1):1460-2. [PUBMED]
  • 31. Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, Kawano K, Kuwae Y, Yamauchi A, Okumura M, Kitamura Y, Oka Y, Kawase I, Sugiyama H, Aozasa K. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol. 2006 Jun;19(6):804-14. [PUBMED]
  • 32. WT1. Genetics Home Reference. Lister Hill National Center for Biomedical Communications. U.S. National Library of Medicine. National Institutes of Health. U.S. Department of Health and Human Services. [http://ghr.nlm.nih.gov/gene/WT1]
  • 33. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013 Jul 4;499(7456):43-9. doi: 10.1038/nature12222. Epub 2013 Jun 23. [PUBMED]
  • 34. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki H, Nagata Y, Yoshida K, Kon A, Suzuki Y, Chiba K, Tanaka H, Niida A, Fujimoto A, Tsunoda T, Morikawa T, Maeda D, Kume H, Sugano S, Fukayama M, Aburatani H, Sanada M, Miyano S, Homma Y, Ogawa S. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013 Aug;45(8):860-7. doi: 10.1038/ng.2699. Epub 2013 Jun 24. [PUBMED]
  • 35. van Vlodrop IJ, Baldewijns MM, Smits KM, Schouten LJ, van Neste L, van Criekinge W, van Poppel H, Lerut E, Schuebel KE, Ahuja N, Herman JG, de Bruine AP, van Engeland M. Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma.Am J Pathol. 2010 Feb;176(2):575-84. doi: 10.2353/ajpath.2010.090442. Epub 2009 Dec 30. [PUBMED]
  • 36. Peters I, Eggers H, Atschekzei F, Hennenlotter J, Waalkes S, Trankenschuh W, Grosshennig A, Merseburger AS, Stenzl A, Kuczyk MA, Serth J. GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression. BJU Int. 2012 Jul;110(2 Pt 2):E144-52. doi: 10.1111/j.1464-410X.2011.10862.x. Epub 2012 Jan 30. [PUBMED]